Empty sella syndrome is a radiological and clinical condition characterized by the herniation of the subarachnoid space into the sella turcica, with filling of the sellar compartment by cerebrospinal fluid and consequent flattening of the gland against the sellar floor. The finding may be partial or complete and does not necessarily indicate endocrine dysfunction, although in some cases it is associated with signs and symptoms that constitute a true “syndrome”, with variable pituitary abnormalities and possible neurological or ophthalmological manifestations. Since the pituitary gland is the central effector of multiple endocrine axes, even an apparently “benign” anatomical deformation may become clinically relevant when it reduces secretory reserve or occurs within specific pathogenetic contexts such as intracranial hypertension.
An essential conceptual point is the distinction between empty sella as an incidental finding and empty sella as a structured clinical condition. In primary forms, the mechanism is often related to a defect or laxity of the sellar diaphragm, allowing cerebrospinal fluid to enter and transmit pulsatile pressure, whereas in secondary forms, empty sella represents the outcome of previous pituitary damage, for example following surgery, radiotherapy, apoplexy or inflammatory processes. Assessment therefore requires an integrated interpretation of the clinical history, hormonal profile and hypothalamic-pituitary imaging, avoiding both the error of dismissing a potentially significant finding and the opposite error of automatically attributing every symptom to empty sella in the absence of clinical consistency.
Empty sella is a relatively common imaging finding, particularly with the widespread use of magnetic resonance imaging performed for headache, nonspecific visual disturbances or other neurological indications. The reported prevalence varies widely because it depends on radiological definitions, imaging quality, inclusion criteria and clinical setting. A substantial proportion of cases are identified incidentally and remain clinically silent, but epidemiological relevance increases when the finding is associated with symptoms or pituitary dysfunction, thereby constituting the “syndrome” in the strict sense.
In primary forms, the epidemiological profile often shows a higher frequency among women and an association with conditions related to intracranial hypertension, particularly in phenotypes in which headache and findings indicating increased pressure coexist with sellar radiological signs. This association is relevant because it shifts the interpretation of the finding from a simple anatomical variation to a possible marker of a cerebrospinal fluid pressure disorder, with implications for clinical assessment and ophthalmological surveillance.
The risk factors differ markedly between primary and secondary forms. In secondary forms, the predominant epidemiological determinant is a history of pituitary injury, including sellar surgery, radiotherapy, apoplexy, postpartum necrosis, infections or infiltrative and autoimmune processes. In these patients, empty sella is often the “anatomical signature” of tissue loss or retraction, and the likelihood of endocrine dysfunction is higher than in primary forms.
Another epidemiologically relevant context is that of patients whose signs or symptoms prompted imaging. Chronic headache, visual disturbances, pulsatile tinnitus or findings compatible with intracranial hypertension make it more likely that empty sella forms part of a broader condition. From this perspective, empty sella is not necessarily the direct cause of the symptoms, but may indicate sellar vulnerability to pressure variations or an underlying systemic or neurological disorder.
Finally, the clinical frequency of pituitary dysfunction in patients with empty sella is heterogeneous and depends on patient selection and assessment criteria. In endocrinological cohorts, in which imaging is performed because of suspected pituitary disease, the likelihood of identifying deficiencies is greater than in unselected radiological populations. This finding is crucial in clinical practice because it requires contextualization: an asymptomatic patient with incidentally detected empty sella does not have the same risk as a patient with compatible symptoms or a history of previous sellar disease.
The pathogenesis of empty sella revolves around the relationship between the sellar compartment, sellar diaphragm, cerebrospinal fluid and pituitary tissue. In primary forms, the most widely accepted model involves a congenital or acquired defect of the sellar diaphragm that allows the subarachnoid space to descend into the sella. Cerebrospinal fluid transmits pressure pulsations that, over time, flatten the gland and redistribute the parenchyma along the sellar floor, with a pituitary stalk that is often elongated but remains in the midline. In this setting, the gland may be anatomically deformed while retaining normal function, or it may have reduced reserve that becomes apparent only during dynamic testing or under conditions of physiological stress.
The association with intracranial hypertension provides an additional pathogenetic dimension. Chronic or intermittent increases in cerebrospinal fluid pressure may facilitate the entry of fluid into the sella and intensify compression of the parenchyma. In this context, empty sella may represent a sign of vulnerability to pressure, together with other neuroradiological findings. The pathophysiology is therefore consistent with a mechanical and dynamic model in which sellar deformation is not a static event, but the result of repeated pressure forces acting on an insufficient diaphragm.
In secondary forms, the etiology is related to loss or retraction of pituitary tissue following an injury. One example is the postsurgical or postradiation outcome, in which the residual parenchyma decreases over time and the sellar space is progressively occupied by cerebrospinal fluid. Similarly, a hemorrhagic or ischemic event such as pituitary apoplexy may lead to necrosis and subsequent tissue involution, evolving into empty sella. Hypophysitis and other infiltrative processes may produce an initial phase of enlargement followed by a fibrotic and atrophic phase, with a final empty sella configuration and frequently persistent endocrine deficiencies.
Endocrine pathophysiology depends on the balance between mechanical compression, microvascular integrity, residual cellular architecture and hypothalamic regulation. The result may be normal function, hyperprolactinemia caused by dopaminergic disinhibition when the stalk is stretched or compressed, or partial or complete hypopituitarism. Growth hormone axis deficiency is frequently reported as one of the most sensitive abnormalities when pituitary reserve declines, whereas corticotropic and thyrotropic involvement, when present, has greater clinical implications and requires rigorous assessment.
An often underestimated point is that empty sella does not define a single mechanism of damage. The same radiological morphology may reflect different processes with different prognoses. Pathophysiology must therefore be interpreted as a coherent sequence involving a predisposing context, pressure dynamics or direct injury, anatomical deformation and, only in a proportion of cases, measurable functional loss. This distinction explains why clinical management must always integrate the anatomical finding with the endocrine phenotype, avoiding automatic correlations.
The clinical presentation of empty sella syndrome is variable and is often dominated by the context in which the finding is identified. Many patients are asymptomatic and empty sella is an incidental finding. When symptoms are present, headache is among the most frequently reported, although its specificity is limited and its assessment must consider neurological comorbidities and the possible role of intracranial hypertension. In some cases, symptoms include nonspecific or fluctuating visual disturbances, which are more often related to concomitant conditions than to empty sella itself, but which nevertheless require structured ophthalmological assessment when risk indicators are present.
Endocrine manifestations depend on the axes involved and the severity of the deficiency. Corticotropic deficiency, when present, may manifest with marked fatigue, hypotension, weight loss, nausea and impaired tolerance to stress, with a risk of rapid deterioration during intercurrent illness. Central hypothyroidism may present with drowsiness, cold intolerance, constipation and cognitive slowing, but may be overlooked when assessment relies solely on thyroid-stimulating hormone. Gonadotropin deficiency may cause amenorrhea, infertility and reduced libido in women, and decreased sexual desire, sexual dysfunction and reduced muscle mass in men, with significant effects on bone health and body composition.
Growth hormone deficiency in adults may contribute to a metabolic phenotype characterized by increased visceral fat, reduced lean mass, dyslipidemia and impaired quality of life, although the presentation is often subtle and overlaps with nonendocrine factors. Hyperprolactinemia may occur as an expression of dopaminergic disconnection, with possible effects on gonadal function, but its interpretation must be cautious and integrated with imaging and the clinical picture.
Posterior pituitary involvement is generally less typical in primary forms, but may occur in secondary forms in which empty sella results from diseases affecting the pituitary stalk and hypothalamic region. When symptoms compatible with polyuria and polydipsia develop, central diabetes insipidus must be considered and assessed, particularly when other signs of sellar or suprasellar disease coexist.
On physical examination, the signs reflect the underlying deficiencies and the clinical context. They may include hypotension, altered body composition, reduced body hair, signs of hypogonadism, bradycardia and dry skin, as well as signs of dehydration in patients with free water loss. The examination should include targeted neurological and ophthalmological assessment when the patient has significant headache, visual disturbances or indirect signs of intracranial hypertension, because in such cases empty sella may represent one component of a broader condition requiring coordinated management.
Clinical suspicion of empty sella syndrome most often arises after identification of the radiological finding rather than from a pathognomonic clinical presentation. However, there are contexts in which the hypothesis should be considered in advance, including chronic headache with signs or findings compatible with intracranial hypertension, unexplained visual disturbances or symptoms consistent with pituitary dysfunction in the absence of evident expansive sellar lesions. In these settings, empty sella may indicate sellar vulnerability or represent the anatomical outcome of a previous process.
A typical context is a patient in whom imaging performed for headache or visual disturbances reveals empty sella, particularly when other features suggesting intracranial hypertension coexist. In this situation, clinical suspicion should not be limited to empty sella as an isolated finding, but should extend to the possibility that the main symptom is driven by the pressure disorder and that empty sella is a marker. This approach is clinically relevant because it redirects attention toward appropriate ophthalmological and neurological assessment in addition to endocrine evaluation.
A second scenario is secondary empty sella in a patient with a history of pituitary surgery, radiotherapy, apoplexy or inflammatory sellar processes such as hypophysitis. In these cases, suspicion should focus on the possibility of persistent or evolving endocrine deficiencies and the need for structured reassessment, because sellar morphology reflects damage or retraction of the parenchyma with potentially reduced reserve.
Suspicion is particularly important when signs compatible with high-risk deficiencies appear, especially symptoms suggestive of secondary adrenal insufficiency, such as hypotension, hypoglycemia and clinical deterioration during stress. Similarly, amenorrhea, infertility, reduced libido, early osteopenia or a progressively worsening metabolic phenotype in a patient with empty sella should prompt comprehensive endocrine assessment, because the unifying diagnosis may be previously unrecognized hypopituitarism.
Finally, the syndrome should be suspected when symptoms are inconsistent with alternative explanations and when empty sella occurs in a patient with multiple “central” abnormalities involving different endocrine axes. In this case, empty sella becomes a finding that requires verification of whether a measurable endocrine pattern exists, distinguishing a simple radiological association from a genuine and treatable functional disorder.
Diagnosis is based on the integration of imaging and functional assessment. The reference imaging technique is contrast-enhanced sellar magnetic resonance imaging, which documents occupation of the sella by cerebrospinal fluid, flattening of the parenchyma and the appearance of the pituitary stalk. The radiological distinction between partial and complete empty sella is useful as a descriptor, but is insufficient to establish clinical relevance. The finding must be correlated with clinical history and endocrine data, because a completely “empty” sella may coexist with preserved function and, conversely, a partial empty sella may be associated with deficiencies in selected clinical contexts.
Initial laboratory assessment must answer a practical question: are clinically significant pituitary deficiencies present that require treatment and prioritized management? The corticotropic axis should be assessed first by measuring morning cortisol and adrenocorticotropic hormone (ACTH), because an unrecognized deficiency exposes the patient to risk during physiological stress. Free thyroxine (FT4) and thyroid-stimulating hormone (TSH) should then be measured for the thyrotropic axis, together with gonadotropins and sex steroids appropriate to sex and clinical context, prolactin, and insulin-like growth factor 1 (IGF-1) as a marker of the growth hormone and IGF-1 axis. Results must be interpreted consistently with physiology and the clinical context, avoiding isolated interpretation of individual values.
For the thyrotropic axis, the diagnosis of central hypothyroidism requires a low or inappropriately low FT4 concentration with a TSH concentration that is not elevated. This point is crucial because using TSH alone as a screening test may miss the diagnosis. For the gonadotropic axis, diagnosis is based on reduced sex steroid concentrations with inappropriately low or normal gonadotropins, interpreted according to age and menopausal status. Growth hormone deficiency cannot be diagnosed from a single growth hormone measurement, and although IGF-1 is useful, it is not always conclusive. In suspected cases, confirmation requires stimulation testing, with the choice of test guided by safety considerations and comorbidities.
Assessment of the posterior pituitary is indicated in the presence of polyuria and polydipsia or suspicious electrolyte abnormalities. In such cases, evaluation for central diabetes insipidus requires a dedicated diagnostic pathway, because empty sella, particularly when secondary, may coexist with diseases involving the pituitary stalk and hypothalamic region. This assessment must be conducted cautiously to avoid misdiagnosis and to ensure appropriate treatment.
A decisive step is determining whether empty sella is primary or secondary. Secondary empty sella is often diagnosed from a history of sellar injury and imaging showing post-treatment or post-event changes. This distinction guides prognosis and follow-up: in secondary forms, the risk of persistent deficiencies is greater and endocrine surveillance tends to be more structured. Complete diagnostic assessment also includes evaluation of complications and target organs, with bone densitometry and metabolic profiling when prolonged gonadal or growth hormone deficiencies are present, because the clinical relevance of empty sella often emerges through the chronic consequences of these deficiencies.
The most useful classification distinguishes primary empty sella from secondary empty sella. In the primary form, the principal mechanism is herniation of cerebrospinal fluid through an insufficient sellar diaphragm, often in association with intracranial pressure dynamics, with a deformed but not necessarily damaged gland. In the secondary form, empty sella is the anatomical outcome of previous pituitary damage, with loss or retraction of the parenchyma after surgery, irradiation, vascular events or inflammatory processes.
A second descriptive level concerns radiological extent: partial when a smaller proportion of the sellar compartment is occupied by cerebrospinal fluid and the gland retains greater thickness, and complete when cerebrospinal fluid occupies most of the sella and the parenchyma appears flattened. This distinction is useful for standardizing radiological reports, but clinical severity is not determined solely by radiological extent. The key issue is correlation with endocrine function and the pathogenetic context.
From a clinical perspective, it is useful to distinguish empty sella as a finding from empty sella syndrome, defined by the presence of symptoms or signs that can consistently be attributed to pituitary dysfunction or to an associated neurological context. This distinction prevents overmedicalization of incidental findings while also protecting against failure to identify treatable deficiencies in symptomatic patients.
Severity may be interpreted along two axes. The first is endocrine severity, defined by the number of axes involved and, more importantly, by the presence of high-risk deficiencies such as corticotropic deficiency. The second is the neurological context, particularly when empty sella is associated with signs of intracranial hypertension and ophthalmological risk. In clinical practice, this dual assessment helps identify patients who require closer follow-up and those who can be managed with an initial evaluation and targeted monitoring.
Finally, classification should include the dynamic dimension. In some secondary forms, residual function may change over time because of progression of the underlying disease or late effects of treatments such as radiotherapy. Stability is more common in primary forms, but the appearance of new symptoms or suspicion of intracranial hypertension requires reassessment. This approach avoids a static classification and makes management more consistent with clinical reality.
Treatment depends on the presence and type of clinical manifestations. When empty sella is an incidental finding and pituitary function is preserved, no specific treatment of the sellar morphology is required, and the approach is based on a complete initial assessment and management of symptoms according to alternative diagnoses. The situation changes when hypopituitarism is present, because treatment is then guided by replacement of deficient axes according to pathophysiological priorities and clinical objectives.
The fundamental safety rule is that correction of adrenal insufficiency must precede thyroid hormone treatment. Replacement with glucocorticoids is intended to provide adequate coverage and reduce the risk of adrenal crisis, with patient education regarding dose adjustment during stress and provision of an emergency plan. Treatment of central hypothyroidism is based on levothyroxine, with dose titration guided by FT4 because TSH is not a reliable marker in central disease.
For gonadotropin deficiency, sex steroid replacement is directed toward well-being, bone protection and sexual function, with the therapeutic strategy selected according to sex, age and individual risk. In fertility pathways, treatment requires specialist induction with exogenous gonadotropins or appropriate reproductive strategies, because sex steroid replacement alone does not restore gametogenesis. Treatment with growth hormone, when indicated, requires a robust diagnosis and monitoring through IGF-1 and clinical assessment, taking metabolic risks into account and considering the need to reassess corticotropic reserve in selected patients.
When empty sella occurs in the context of intracranial hypertension, management must address the underlying condition in collaboration with neurological and ophthalmological specialists. In this setting, the therapeutic objective is to prevent visual damage and control symptoms, while empty sella is interpreted as an associated sign rather than a direct treatment target. Treatment is therefore not directed at empty sella in an anatomical sense, but at the underlying disorder responsible for its pathogenesis.
In secondary forms, treatment also includes management of the causative disease when it remains active, for example residual tumors, postinflammatory changes or infiltrative disorders. In these cases, the approach is multidisciplinary and integrates neuroradiological surveillance with endocrine stabilization, because functional prognosis depends on control of the underlying process and optimization of replacement therapy over time.
Follow-up should be tailored according to whether the condition is primary or secondary, the presence of symptoms and the initial endocrine status. In a patient with incidentally detected empty sella and a normal hormonal profile, the most rational approach is targeted clinical reassessment over time, focused on the development of new symptoms and the emergence of potential risk contexts. Conversely, when documented endocrine deficiencies or secondary empty sella are present, follow-up must be structured and continuous because replacement therapy requires adjustment and residual function may change.
For the corticotropic axis, follow-up includes education regarding stress-dose adjustment, prevention of chronic overtreatment and specialist reassessment when functional recovery is possible, always using appropriate testing under safe conditions. For central hypothyroidism, monitoring is based on FT4 and the clinical picture, with attention to interactions between thyroid hormone and glucocorticoid therapy and to conditions that modify treatment requirements.
Follow-up of the gonadotropic axis is guided by reproductive goals and prevention of bone loss. Bone densitometry and fracture risk assessment are cross-cutting components, particularly in prolonged deficiencies or disorders involving multiple axes. For the growth hormone axis, when treatment is being administered, monitoring includes IGF-1, symptoms, body composition and metabolic parameters, with cautious dose titration and attention to edema, arthralgia and blood glucose.
When intracranial hypertension or visual symptoms are present, follow-up should include ophthalmological surveillance directed toward preventing optic nerve damage. In these patients, empty sella is one component of the overall condition, and the priority is preservation of visual stability. Neuroradiological imaging may be repeated according to the clinical context, particularly when progression of the pressure disorder is suspected or when sellar anatomy is interpreted in relation to causative diseases.
In secondary forms, neuroradiological follow-up is often part of the management pathway because empty sella may coexist with residual tumors or complex sequelae. In these cases, integrated monitoring helps prevent underdiagnosis of late-onset deficiencies and enables optimization of replacement therapy. A final component of follow-up is quality of life: fatigue, mood alterations and reduced performance may persist even when laboratory parameters are considered “acceptable” if treatment is not tailored to the patient. Assessment must therefore remain clinically centered rather than being based exclusively on laboratory values.
Prognosis depends primarily on the type of empty sella and the associated functional profile. In incidental primary forms with preserved pituitary function, the outcome is generally favorable and the condition may remain stable over time. However, prognosis must be interpreted in light of the clinical context: when the finding is associated with intracranial hypertension, the outcome depends mainly on control of the pressure disorder and preservation of visual function.
In secondary forms, endocrine prognosis is more often determined by persistent pituitary damage. Deficiencies may be permanent and require long-term replacement therapy. Corticotropic deficiency is particularly important because it exposes the patient to the risk of adrenal crisis during infections, vomiting or surgical procedures if it is not managed correctly. Prevention through education and emergency planning is therefore an integral component of prognosis and reduces avoidable acute events.
Long-term complications are largely those of unrecognized or inadequately treated hypopituitarism. Gonadal deficiency and growth hormone deficiency contribute to metabolic risk, cardiovascular risk and loss of lean mass, while prolonged hypogonadism increases the risk of osteopenia and fractures. Inadequately treated central hypothyroidism may worsen the lipid profile, cognitive well-being and functional capacity. These complications can be prevented through appropriate replacement therapy and follow-up focused on clinical outcomes as well as laboratory values.
From a neurological perspective, the most relevant complication in settings associated with intracranial hypertension is visual damage, which may be prevented through ophthalmological surveillance and appropriate management of the underlying condition. Persistent headache and nonspecific visual disturbances may impair quality of life and require an assessment that avoids automatically attributing them to the sellar finding, while maintaining an open and clinically consistent diagnostic approach.
In summary, prognosis is favorable when empty sella is incidental and pituitary function is intact, whereas it becomes more complex when empty sella is secondary or when endocrine deficiencies or neurological conditions such as intracranial hypertension coexist. The most important complications can be prevented through comprehensive initial assessment, definition of the pathogenetic context and follow-up directed toward endocrine, metabolic, skeletal and visual stability.